This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Merck & Co., Inc.

Drug Names(s): MK-0524A (ER niacin/laropiprant) combined with Simvastatin; MK0524B

Description: MK-0524B is MK-0524A combined with simvastatin.

MK-0524A is extended-release niacin combined with a flushing pathway inhibitor (MK-0524), which is a selective antagonist of the DP1 receptor. DP1 is a receptor for the vasodilatory prostaglandin D2, and is also called PGD2 receptor 1.

Simvastatin inhibits HMG-CoA reductase, an enzyme required for the synthesis of cholesterol.

MK-0524B News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug